Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma
Status:
Not yet recruiting
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of 1st line therapy with gemcitabine plus S1
and tislelizumab in participants with advanced biliary tract carcinoma (BTC).